Penumbra/PEN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Penumbra
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Ticker
PEN
Sector
Healthcare
Trading on
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Alameda, United States
Employees
4,200
Website
www.penumbrainc.com
Penumbra Metrics
BasicAdvanced
$6.8B
Market cap
74.03
P/E ratio
$2.38
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$6.8B
Beta
0.57
Financial strength
Current ratio
6.119
Quick ratio
3.308
Long term debt to equity
18.083
Total debt to equity
19.23
Interest coverage (TTM)
55.57%
Management effectiveness
Return on assets (TTM)
4.03%
Return on equity (TTM)
8.38%
Valuation
Price to earnings (TTM)
74.03
Price to revenue (TTM)
6.19
Price to book
5.63
Price to tangible book (TTM)
7
Price to free cash flow (TTM)
64.98
Growth
Revenue change (TTM)
23.87%
Earnings per share change (TTM)
1,293.03%
3-year revenue growth
22.76%
3-year earnings per share growth
153.18%
What the Analysts think about Penumbra
Analyst Ratings
Majority rating from 16 analysts.
Penumbra Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$279M
-2.11%
Net income
$11M
-79.70%
Profit margin
3.94%
-79.31%
Penumbra Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.43
$0.67
$0.76
$0.41
-
Expected
$0.28
$0.45
$0.70
$0.38
$0.57
Surprise
54.29%
47.32%
8.63%
8.38%
-
Penumbra News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $6.8B as of July 04, 2024.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 74.03 as of July 04, 2024.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Penumbra stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.